Journal of Clinical Medicine Research

breast cancer is one of the three most common types of cancer in the world, which not only has a high incidence rate, but also is a malignant tumor. In particular, HER2 positive breast cancer has been diagnosed as the most aggressive type of cancer in clinical practice. However, since the emergence of HER2 targeted drugs, it has significant implications for improving patients' quality of life. Especially for early high-risk patients, targeted therapy can improve patient prognosis; However, if the patient is in the late stage of cancer, targeted therapy drugs should be selected reasonably to achieve the goal of prolonging the patient's survival.